Research programme: metformin controlled release - Spencer PharmaceuticalAlternative Names: Met4
Latest Information Update: 16 Jul 2016
At a glance
- Originator Spencer Pharmaceutical
- Class Antihyperglycaemics; Biguanides; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 24 Aug 2010 Preclinical trials in Type-2 diabetes mellitus in USA (PO)